David Ricks, Eli Lilly CEO (Photographer: Jeenah Moon/Bloomberg via Getty Images)
August 8, 2024 01:38 PM EDT
Pharma

Lil­ly says to ‘take some cau­tion’ on oth­er com­pa­nies’ ear­ly-stage obe­si­ty da­ta, calls out com­pounders

Kyle LaHucik

Senior Reporter

Af­ter post­ing a blowout quar­ter of fi­nan­cial re­sults, Eli Lil­ly has al­most made the obe­si­ty busi­ness look easy. But amid in­vestors’ en­thu­si­asm …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Tang Cap­i­tal’s Con­cen­tra bids for Sin­gu­lar Ge­nomics days af­ter Deer­field of­fer

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times